[Primary and follow-up studies of patients with carcinoid metastases using indium 111 octreotide--rational use of Sandostatin].
Carcinoids may express Somatostatin receptors. Therefore, a Somatostatin-analogue, In-111 Octreotide (OctreoScan), was used for their demonstration. A total of 6 patients who presented with radiologically verified carcinoid-metastases was examined. In order to control tumor progress, 4 of these patients were reexamined within a period of 3 to 11 months. All of the radiological findings were confirmed scintigraphically, except some small retroperitoneally located lymph nodes. The follow-up examinations of 2 patients revealed additional metastases by scintigraphy only. There were no false positive results. The results of OctreoScan scintigraphy may be used for predicting the success of receptor-specific therapies and therefore, permit the rational and efficient application of Sandostatin.
Lipp
R W
RW
Abteilungen für Nuklearmedizin und Endokrinologie, Medizinischen Universitätsklinik, Karl-Franzens-Universität, Graz.
Hammer
H F
HF
Passath
A
A
Dobnig
H
H
Ramschak-Schwarzer
S
S
Stiegler
C
C
Leb
G
G
Krejs
G J
GJ
D000368:Aged; D002276:Carcinoid Tumor / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007205:Indium Radioisotopes; D007414:Intestinal Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy; D008113:Liver Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000556:secondary*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D011877:Radionuclide Imaging
D007205:Indium Radioisotopes; D015282:Octreotide
Primär- und Verlaufsuntersuchungen von Patienten mit Karzinoidmetastasen mittels Indium-111-Octreotid--Rationale Anwendung von Sandostatin.